ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Could PMN be a prime target for acquisition

<< Previous

Bullboard Posts

Next >>

Comment by BottomBrokeron Apr 20, 2023 2:03pm

60 Views

Post# 35405745

RE:Could PMN be a prime target for acquisition

What would a partnership/acquisition look like exactly?

It's my understanding (and I could be totally wrong), that we as shareholders would either get straight-up cash, or an option to convert shares to the new company, or a combination of both????

What's the most desirable outcome for us?

<< Previous

Bullboard Posts

Next >>

The Market Online’s Weekly Gold Report – Nov. 27, 2024